Aptargroup - ATR STOCK NEWS

Aptar Pharma, through its subsidiary Nanopharm, has partnered with Fluidda to expedite the FDA approval process for orally inhaled generic products. This collaboration utilizes Nanopharm's SmartTrack™ and Fluidda's Functional Respiratory Imaging technologies to streamline drug applications, potentially reducing the need for extensive clinical studies. The first approval using this alternative bioequivalence pathway is pending, promising to enhance demand for their collective services and solidify their positions in respiratory drug development.

AptarGroup, Inc. (NYSE: ATR) has announced the appointment of Matt Trerotola to its Board of Directors. Trerotola, the President and CEO of Enovis Corporation, brings over 30 years of experience in medical technology and significant expertise in driving organic growth, profitability, and strategic acquisitions. His extensive background includes leadership roles at DuPont and Danaher Corporation. Aptar's President and CEO expressed confidence that Trerotola's insights will enhance shareholder value. This strategic addition aligns with Aptar's commitment to improve lives globally through innovative solutions.

AptarGroup, Inc. (NYSE: ATR) reported a 15% increase in net income to $64 million for the second quarter of 2022, alongside 4% sales growth totaling $845 million. Core sales also rose 10%. Key growth drivers included robust Pharma and Beauty + Home segments, with core sales up 12% and 10%, respectively. Adjusted EPS climbed 13% to $0.96. The company faces challenges from inflation and currency fluctuations but remains optimistic about future performance, expecting EPS between $0.90 and $1.00 for Q3.

AptarGroup, Inc. (NYSE: ATR) announced a quarterly cash dividend of $0.38 per share, payable on August 17, 2022, to stockholders on record as of July 27, 2022. The company will also hold a conference call on July 29, 2022, at 8:00 a.m. Central Time to discuss its second quarter results for 2022. As a leader in drug delivery and consumer product dispensing, Aptar aims to enhance the lives of millions through its innovative solutions across various markets.

AptarGroup, Inc. (NYSE: ATR) has been recognized as one of 3BL Media's 100 Best Corporate Citizens for the second consecutive year, highlighting its commitment to environmental, social, and governance (ESG) practices. This ranking evaluates the largest U.S. public companies on 155 ESG factors. CEO Stephan B. Tanda emphasized the company’s dedication to sustainable solutions and collaboration with industry partners. Similarly, VP Beth Holland noted Aptar's proactive approach to achieving circular economy goals. The recognition reflects Aptar's ongoing efforts towards transparency and sustainability.

AptarGroup, Inc. (NYSE:ATR) reported a 9% increase in first-quarter sales, reaching $845 million, boosted by double-digit core growth in all segments. Adjusted earnings per share were $0.96, down from $1.05 the previous year, impacted by a higher effective tax rate. The Pharma segment experienced significant growth due to rising demand for allergy and asthma products. Despite operational challenges, including currency headwinds and supply chain issues, the company remains optimistic about future growth. A quarterly dividend of $0.38 was declared, with share repurchases continuing.

AptarGroup, Inc. (NYSE: ATR) has declared a quarterly cash dividend of $0.38 per share, scheduled for payment on May 18, 2022. The record date for shareholders will be April 27, 2022. A conference call to discuss the first quarter results for 2022 is set for April 29, 2022, at 8:00 a.m. Central Time. Aptar is a leader in drug delivery and consumer product dispensing, employing approximately 13,000 individuals across 20 countries.

AptarGroup, Inc. (NYSE: ATR) announces the sad passing of director Jesse Wu, who served on the Board since 2018 and was part of the Management Development & Compensation Committee. The company expresses deep condolences to his family, highlighting Wu's significant contributions, particularly in the Asian market. Aptar is a global leader in drug delivery and consumer product solutions, with 13,000 employees across 20 countries.